ARAV vs. MBIO, BPTS, AGRX, CYCC, NBY, BPTSY, ARDS, ONCO, VRPX, and CYTO
Should you be buying Aravive stock or one of its competitors? The main competitors of Aravive include Mustang Bio (MBIO), Biophytis (BPTS), Agile Therapeutics (AGRX), Cyclacel Pharmaceuticals (CYCC), NovaBay Pharmaceuticals (NBY), Biophytis (BPTSY), Aridis Pharmaceuticals (ARDS), Onconetix (ONCO), Virpax Pharmaceuticals (VRPX), and Altamira Therapeutics (CYTO). These companies are all part of the "pharmaceutical preparations" industry.
Mustang Bio (NASDAQ:MBIO) and Aravive (NASDAQ:ARAV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
10.0% of Mustang Bio shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 2.1% of Mustang Bio shares are owned by company insiders. Comparatively, 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Mustang Bio received 64 more outperform votes than Aravive when rated by MarketBeat users. Likewise, 64.12% of users gave Mustang Bio an outperform vote while only 62.28% of users gave Aravive an outperform vote.
Mustang Bio currently has a consensus price target of $17.25, suggesting a potential upside of 6,534.62%. Aravive has a consensus price target of $13.50, suggesting a potential upside of 33,565.84%. Given Mustang Bio's higher probable upside, analysts clearly believe Aravive is more favorable than Mustang Bio.
Mustang Bio has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Aravive has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.
Mustang Bio has higher earnings, but lower revenue than Aravive. Mustang Bio is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.
Mustang Bio has a net margin of 0.00% compared to Mustang Bio's net margin of -569.65%. Mustang Bio's return on equity of 0.00% beat Aravive's return on equity.
In the previous week, Mustang Bio had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Mustang Bio and 0 mentions for Aravive. Aravive's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.
Summary
Aravive beats Mustang Bio on 9 of the 16 factors compared between the two stocks.
Get Aravive News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
